A citation-based method for searching scientific literature

Mark M Smits, Daniel H van Raalte, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, Djuna L Cahen. Gut 2016
Times Cited: 24







List of co-cited articles
211 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
50

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
33

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, Indra C Pieters, Djuna L Cahen, Michaela Diamant, Daniël H van Raalte. BMJ Open 2015
26
29

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
29

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
M H A Muskiet, L Tonneijck, M M Smits, M H H Kramer, M Diamant, J A Joles, D H van Raalte. Diabetes Obes Metab 2016
43
20

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
20

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
20

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Lennart Tonneijck, Mark M Smits, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, A H Jan Danser, Piet M Ter Wee, Michaela Diamant, Jaap A Joles, Daniël H van Raalte. Diabetes Care 2016
53
20

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
768
20

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits, Michaël J B van Baar, Mark H H Kramer, Ewout J Hoorn, Jaap A Joles, Daniël H van Raalte. Nat Rev Nephrol 2017
126
20

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
570
20

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
697
16

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, Michaela Diamant, Max Nieuwdorp, Albert K Groen, Djuna L Cahen, Daniël H van Raalte. Diabetes Obes Metab 2016
28
16

Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
M M Smits, L Tonneijck, M H A Muskiet, M H H Kramer, D L Cahen, D H van Raalte. Diabetes Obes Metab 2016
39
16

Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability.
Yuki Nakatani, Atsuhiko Kawabe, Mihoko Matsumura, Yoshimasa Aso, Takanori Yasu, Nobuyuki Banba, Takaaki Nakamoto. Diabetes Care 2016
32
16

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Feng Sun, Shanshan Wu, Shuxia Guo, Kai Yu, Zhirong Yang, Lishi Li, Yuan Zhang, Xiaochi Quan, Linong Ji, Siyan Zhan. Diabetes Res Clin Pract 2015
133
16

Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men.
Ali Asmar, Lene Simonsen, Meena Asmar, Sten Madsbad, Jens J Holst, Erik Frandsen, Cedric Moro, Thomas Jonassen, Jens Bülow. Am J Physiol Endocrinol Metab 2015
42
16

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
16


Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.
L van Bloemendaal, J S Ten Kulve, S E la Fleur, R G Ijzerman, M Diamant. J Endocrinol 2014
124
16

Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.
Jeppe Skov, Anders Dejgaard, Jørgen Frøkiær, Jens Juul Holst, Thomas Jonassen, Søren Rittig, Jens Sandahl Christiansen. J Clin Endocrinol Metab 2013
109
16

Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
Jennifer S Ten Kulve, Dick J Veltman, Liselotte van Bloemendaal, Frederik Barkhof, Madeleine L Drent, Michaela Diamant, Richard G IJzerman. Diabetes Care 2016
38
16

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
440
16

Metformin and the gastrointestinal tract.
Laura J McCreight, Clifford J Bailey, Ewan R Pearson. Diabetologia 2016
248
12

Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
Jutta Keller, Michael E Trautmann, Harry Haber, Lai San Tham, Tamsin Hunt, Kenneth Mace, Helle Linnebjerg. Regul Pept 2012
38
12

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.
Adil E Bharucha, Nisha Charkoudian, Christopher N Andrews, Michael Camilleri, David Sletten, Alan R Zinsmeister, Phillip A Low. Am J Physiol Regul Integr Comp Physiol 2008
64
12

Cardiovascular actions of incretin-based therapies.
John R Ussher, Daniel J Drucker. Circ Res 2014
231
12

Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance.
Kim A Sjøberg, Stephen Rattigan, Jacob F Jeppesen, Anne-Marie Lundsgaard, Jens J Holst, Bente Kiens. J Physiol 2015
17
17

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
Daniel J Cuthbertson, Andrew Irwin, Chris J Gardner, Christina Daousi, Tej Purewal, Niall Furlong, Niru Goenka, E Louise Thomas, Valerie L Adams, Sudeep P Pushpakom,[...]. PLoS One 2012
140
12

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
An Tang, Rémi Rabasa-Lhoret, Hélène Castel, Claire Wartelle-Bladou, Guillaume Gilbert, Karine Massicotte-Tisluck, Gabriel Chartrand, Damien Olivié, Anne-Sophie Julien, Jacques de Guise,[...]. Diabetes Care 2015
69
12

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.
Mark M Smits, Marcel H A Muskiet, Lennart Tonneijck, Trynke Hoekstra, Mark H H Kramer, Michaela Diamant, Daniël H van Raalte. Br J Clin Pharmacol 2016
39
12

Pulse contour cardiac output derived from non-invasive arterial pressure in cardiovascular disease.
L W J Bogert, K H Wesseling, O Schraa, E J Van Lieshout, B A J M de Mol, J van Goudoever, B E Westerhof, J J van Lieshout. Anaesthesia 2010
144
12

Investigation of the haemodynamic effects of exenatide in healthy male subjects.
Buddhike Mendis, Elizabeth Simpson, Ian MacDonald, Peter Mansell. Br J Clin Pharmacol 2012
38
12

Functional interactions between the gut microbiota and host metabolism.
Valentina Tremaroli, Fredrik Bäckhed. Nature 2012
12

Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.
Anne Vrieze, Els Van Nood, Frits Holleman, Jarkko Salojärvi, Ruud S Kootte, Joep F W M Bartelsman, Geesje M Dallinga-Thie, Mariette T Ackermans, Mireille J Serlie, Raish Oozeer,[...]. Gastroenterology 2012
12

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
344
12



Glucagon-like peptide analogues for type 2 diabetes mellitus.
Deepson S Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman Waugh, Alisa Snaith. Cochrane Database Syst Rev 2011
149
12

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, Petra J W Pouwels, Indra C Pieters-van den Bos, Trynke Hoekstra, Michaela Diamant, Daniël H van Raalte, Djuna L Cahen. Diabetologia 2016
62
12


Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes.
Julie A Lovshin, Harindra Rajasekeran, Yulyia Lytvyn, Leif E Lovblom, Shajiha Khan, Robel Alemu, Amy Locke, Vesta Lai, Huaibing He, Lucinda Hittle,[...]. Diabetes Care 2017
63
12

Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Katherine R Tuttle, T Dwight McKinney, Jaime A Davidson, Greg Anglin, Kristine D Harper, Fady T Botros. Diabetes Obes Metab 2017
35
12

Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
Katherine R Tuttle, Cory Heilmann, Byron J Hoogwerf, Carl Brown, Pamela W Anderson. Am J Kidney Dis 2013
20
15

Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
J Skov, M Pedersen, J J Holst, B Madsen, J P Goetze, S Rittig, T Jonassen, J Frøkiaer, A Dejgaard, J S Christiansen. Diabetes Obes Metab 2016
61
12

Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.
Feng Sun, Shanshan Wu, Jing Wang, Shuxia Guo, Sanbao Chai, Zhirong Yang, Lishi Li, Yuan Zhang, Linong Ji, Siyan Zhan. Clin Ther 2015
89
12

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
12

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Nat Rev Endocrinol 2016
140
12

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Lennart Tonneijck, Mark M Smits, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, A H Jan Danser, Michaela Diamant, Jaap A Joles, Daniël H van Raalte. Diabetologia 2016
57
12

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Erik J van Bommel, Hiddo J L Heerspink, Daniël H van Raalte, Jaap A Joles. J Am Soc Nephrol 2017
206
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.